Multiple myeloma diagnostics market is likely to record a promising CAGR 10.3% during the forecast period. The market is currently valued at US$ 13.62 Bn and is likely to reach US$ 32.91 Bn by 2032.
| Attributes | Details |
| Multiple Myeloma Diagnostics Market CAGR (2022-2032) | 10.3% |
| Multiple Myeloma Diagnostics Market Value (2022) | US$ 13.62 Bn |
| Multiple Myeloma Diagnostics Market Value (2032) | US$ 32.91 Bn |
Multiple plasma cells help in fighting various infections, but malignant plasma cells accumulate in bone marrow restricts the basic functionality of a plasma cell. The “M” or the antibody protein extracted from malignant plasma cells causes bone destruction, tumor, kidney damage and restricts immune functions. As these types of diseases increase in number day by day, there is a push in demand for multiple myeloma diagnostics.
Awareness about health and the increasing number of patients suffering from cancer and other chronic diseases are also pushing the sales of multiple myeloma diagnostics systems. Also, increased funding from governments for the setup of these diagnostics centers is hyping up the demand for multiple myeloma diagnostics.
Plasma cells help in fighting infection; however, malignant plasma cells in multiple myeloma accumulate in the bone marrow, which blocks the normal function of plasma cells. The M protein, which is an abnormal antibody produced by malignant plasma cells, causes tumors, bone destruction, kidney damage, and damaged immune function.
However, in recent years, ten new drugs have received approval in a short period of time due to the formation of the Multiple Myeloma Research Foundation and the increasing attention, advancement, and research for multiple myeloma diagnostics and therapies. These factors help in increasing the demand for multiple myeloma diagnostics.
These factors contribute to the growth of the multiple myeloma diagnostics market. Moreover, increasing funding for the research and development and rising clinical trials is expected to provide the most promising multiple myeloma treatments options and will boost the growth of the multiple myeloma diagnostics market.
Technological advancement and rising clinical studies for the management of multiple myeloma are the main factors to boost the market growth of the multiple myeloma diagnostics market.
Additionally, rising disposable income is expected to boost the growth of the multiple myeloma diagnostics market. However, lack of awareness and expertise can lead to complications and can damage the immune function of the heart, which may lead to heart failure. The poor management of multiple myeloma may lead to restraint the growth of the multiple myeloma diagnostics market.
The Asia Pacific multiple myeloma diagnostics market is expected to show fast growth due to rising heart-related problems and a lack of awareness regarding the management of multiple myeloma.
The multiple myeloma diagnostics market is expected to be dominated by North America due to advanced healthcare infrastructure and reimbursement in the region.
Latin America Multiple myeloma diagnostics market is expected to experience steady growth due to a lack of expertise in the region. Europe is expected to score second place in the multiple myeloma diagnostics market due to the availability of skilled healthcare professionals coupled with higher adoption in the region.
The Middle East & Africa is expected to be the least lucrative multiple myeloma diagnostics market due to the least product availability and lack of facilities in the region.
The key players of the multiple myeloma diagnostics market are focusing on enhancing and adopting strategies like mergers, approvals, upgrades and extending centers to drive the demand for multiple myeloma diagnostics business. This is driving the sales of Multiple myeloma diagnostics.
Key players in multiple myeloma diagnostics market include Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Genzyme Corporation, Thermo Fisher Scientific Inc, Celgene Corporation, Millennium Pharmaceuticals, Norvartis AG, Amgen Inc, Juno Therapeutics, Janssen Biotech Inc, Johnson & Johnson, GlaxoSmithKline plc, Pfizer, AbbVie Inc, Onyx Pharmaceuticals, Celldex Theapeutics Inc and Innate Pharma SA.
| Report Attribute | Details |
| Growth Rate | CAGR of 10.3% from 2022 to 2032 |
| Base year for estimation | 2021 |
| Historical data | 2015 - 2020 |
| Forecast period | 2022 - 2032 |
| Quantitative units | Revenue in USD billion, volume in kilotons, and CAGR from 2022 to 2032 |
| Report coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis, |
| Segments covered | Drug Type, Distribution Channel, Region |
| Regional scope | North America; Western Europe, Eastern Europe, Middle East, Africa, ASEAN, South Asia, Rest of Asia, Australia and New Zealand |
| Country scope | U.S.; Canada; Mexico; Germany; U.K.; France; Italy; Spain; Russia; Belgium; Poland; Czech Republic; China; India; Japan; Australia; Brazil; Argentina; Colombia; Saudi Arabia; UAE; Iran; South Africa |
| Key companies profiled | Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Genzyme Corporation, Celgene Corporation, Millennium Pharmaceuticals, Norvartis AG, Amgen Inc, Juno Therapeutics, Janssen Biotech Inc, Johnson & Johnson, GlaxoSmithKline plc, Pfizer, AbbVie Inc, Onyx Pharmaceuticals, Celldex Theapeutics Inc and Innate Pharma SA, |
| Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
Institutional sales is the biggest segment in the multiple myeloma diagnostics market by distribution channel and is expected to hold a big portion of the market in the forecast period. The leading factor is the easy availability due to strong supply chain. This leads to the high demand for Multiple myeloma diagnostics in developing countries.
Key competitors holding substantial multiple myeloma diagnostics market share are Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Genzyme Corporation, Celgene Corporation, Millennium Pharmaceuticals, Norvartis AG, Amgen Inc, Juno Therapeutics, Janssen Biotech Inc, Johnson & Johnson, GlaxoSmithKline plc, Pfizer, AbbVie Inc, Onyx Pharmaceuticals, Celldex Theapeutics Inc and Innate Pharma SA,
Demand for Multiple myeloma diagnostics is likely to rise with increasing number of patients that suffer from disease generated by malignant cells, increasing awareness and inactive lifestyle leading up to new diseases, increasing the sales of multiple myeloma diagnostics.
Our Research Products
The "Full Research Suite" delivers actionable market intel, deep dives on markets or technologies, so clients act faster, cut risk, and unlock growth.
The Leaderboard benchmarks and ranks top vendors, classifying them as Established Leaders, Leading Challengers, or Disruptors & Challengers.
Locates where complements amplify value and substitutes erode it, forecasting net impact by horizon
We deliver granular, decision-grade intel: market sizing, 5-year forecasts, pricing, adoption, usage, revenue, and operational KPIs—plus competitor tracking, regulation, and value chains—across 60 countries broadly.
Spot the shifts before they hit your P&L. We track inflection points, adoption curves, pricing moves, and ecosystem plays to show where demand is heading, why it is changing, and what to do next across high-growth markets and disruptive tech
Real-time reads of user behavior. We track shifting priorities, perceptions of today’s and next-gen services, and provider experience, then pace how fast tech moves from trial to adoption, blending buyer, consumer, and channel inputs with social signals (#WhySwitch, #UX).
Partner with our analyst team to build a custom report designed around your business priorities. From analysing market trends to assessing competitors or crafting bespoke datasets, we tailor insights to your needs.
Supplier Intelligence
Discovery & Profiling
Capacity & Footprint
Performance & Risk
Compliance & Governance
Commercial Readiness
Who Supplies Whom
Scorecards & Shortlists
Playbooks & Docs
Category Intelligence
Definition & Scope
Demand & Use Cases
Cost Drivers
Market Structure
Supply Chain Map
Trade & Policy
Operating Norms
Deliverables
Buyer Intelligence
Account Basics
Spend & Scope
Procurement Model
Vendor Requirements
Terms & Policies
Entry Strategy
Pain Points & Triggers
Outputs
Pricing Analysis
Benchmarks
Trends
Should-Cost
Indexation
Landed Cost
Commercial Terms
Deliverables
Brand Analysis
Positioning & Value Prop
Share & Presence
Customer Evidence
Go-to-Market
Digital & Reputation
Compliance & Trust
KPIs & Gaps
Outputs
Full Research Suite comprises of:
Market outlook & trends analysis
Interviews & case studies
Strategic recommendations
Vendor profiles & capabilities analysis
5-year forecasts
8 regions and 60+ country-level data splits
Market segment data splits
12 months of continuous data updates
DELIVERED AS:
PDF EXCEL ONLINE
Multiplex Sepsis Biomarker Panels Market Size and Share Forecast Outlook 2025 to 2035
Multiplex Protein Profiling Market Size and Share Forecast Outlook 2025 to 2035
Multiplex Biomarker Imaging Market Forecast and Outlook 2025 to 2035
Multiplex PCR Assays Market Size and Share Forecast Outlook 2025 to 2035
Multiple Reaction Monitoring Assay Market Size and Share Forecast Outlook 2025 to 2035
Multiple System Atrophy (MSA) Therapeutics Market Size and Share Forecast Outlook 2025 to 2035
MUPS Market Overview - Growth & Forecast 2025 to 2035
Multiple Endocrine Neoplasia Market
Multiplex Assay Market
Multiplex Molecular Diagnostics Market Size and Share Forecast Outlook 2025 to 2035
Syndromic Multiplex Diagnostic Market
Wavelength Division Multiplexing (WDM) Equipment Market Analysis - Size, Growth, and Forecast 2025 to 2035
DNA Diagnostics Market Size and Share Forecast Outlook 2025 to 2035
HIV Diagnostics Market Size and Share Forecast Outlook 2025 to 2035
Food Diagnostics Services Market Size, Growth, and Forecast for 2025–2035
Rabies Diagnostics Market Size and Share Forecast Outlook 2025 to 2035
Cancer Diagnostics Market Analysis - Size, Share and Forecast 2025 to 2035
Tissue Diagnostics Market Size and Share Forecast Outlook 2025 to 2035
Sepsis Diagnostics Market Growth - Trends & Forecast 2025 to 2035
Poultry Diagnostics Market - Demand, Growth & Forecast 2025 to 2035
Multiple Myeloma Diagnostics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
Chat With
MaRIA
